Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A morphologic variant of chondrosarcoma arising from bone and soft tissue. It is characterized by the presence of malignant small round cells, biphasic growth pattern, and well differentiated hyaline cartilage. Clinical presentation includes pain and swelling. The clinical course is aggressive, with local recurrences and distant metastases.
Biomarker and diagnostic research for mesenchymal chondrosarcoma has been reported in the published literature.
4 clinical trials registered, 1 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 3 PHASE2. Research is primarily sponsored by academic and government institutions.
46 publications have been identified in PubMed for mesenchymal chondrosarcoma. Research spans Case Report / Case Series (50%), Review / Meta-Analysis (27%), and Diagnostic / Biomarker (7%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 22 |
Data assembled from 3 of 12 sources · Last updated Oct 4, 2026, 6:16 AM UTC
Research summaries | 12 | 27% |
Testing and diagnosis research | 3 | 7% |
Laboratory research | 2 | 5% |
Disease patterns and progression | 2 | 5% |
New treatment approaches | 2 | 5% |
Clinical study results | 1 | 2% |
Leal Lopez A (2026). [PMID: 41731714](https://pubmed.ncbi.nlm.nih.gov/41731714/). *Int J Surg Pathol*. [Case Report / Case Series]
Baldi GG (2026). [PMID: 41650748](https://pubmed.ncbi.nlm.nih.gov/41650748/). *ESMO Open*. [Epidemiology / Natural History]
Persons JE (2026). [PMID: 41855049](https://pubmed.ncbi.nlm.nih.gov/41855049/). *J Neuropathol Exp Neurol*. [Case Report / Case Series]
Çalışkan Kamış Ş (2026). [PMID: 41867924](https://pubmed.ncbi.nlm.nih.gov/41867924/). *Front Pediatr*. [Case Report / Case Series]
Nagy A (2026). [PMID: 41930936](https://pubmed.ncbi.nlm.nih.gov/41930936/). *Adv Anat Pathol*. [Diagnostic / Biomarker]
Ichikawa J (2026). [PMID: 41941232](https://pubmed.ncbi.nlm.nih.gov/41941232/). *Clin Nucl Med*. [Case Report / Case Series]
Bedell M (2025). [PMID: 39528823](https://pubmed.ncbi.nlm.nih.gov/39528823/). *Virchows Arch*. [Review / Meta-Analysis]
Wagner MJ (2025). [PMID: 40117529](https://pubmed.ncbi.nlm.nih.gov/40117529/). *JCO Precis Oncol*. [Gene Therapy / Novel Therapeutics]
Dashti NK (2025). [PMID: 40716921](https://pubmed.ncbi.nlm.nih.gov/40716921/). *Surg Pathol Clin*. [Review / Meta-Analysis]
Luo Q (2025). [PMID: 39852313](https://pubmed.ncbi.nlm.nih.gov/39852313/). *J Int Med Res*. [Case Report / Case Series]
AI-curated news mentioning mesenchymal chondrosarcoma
Updated Feb 5, 2026
A multicentre retrospective analysis by the Italian Sarcoma Group evaluates the activity of chemotherapy in mesenchymal chondrosarcoma. This study provides insights into treatment efficacy for this rare sarcoma subtype.